Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib + Hypofractionated Radiotherapy in Locally Advanced Pancreatic Cancer
NCT04172532Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peposertib in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started Jan 2021; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04172532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172532.